The progress of early cancer diagnoses in clinical laboratories

X.SongxiaoX.Songxiao
BulletArticle
RED 2024 Operational Excellence
แชร์สิ่งนี้:
คัดลอกลิงก์

Early diagnosis of cancer is critically important for the ideal prognosis of cancer patients. cfDNA-based new technologies have the potential to be the methodology for liquid biopsy of early cancer patients. Dr Xu Songxiao of Zhejiang Cancer Hospital discusses the progress of cfDNA methylation, fragmentome and microbiome studies, as well as the combined application of current biomarkers in this talk at RED 2024.

 

แชร์สิ่งนี้:
คัดลอกลิงก์

เพิ่มเติมในหัวข้อเดียวกัน

How diagnostics innovation empowers high-quality development in hospitals

Dr Gurpreet Singh on digital twins in healthcare and its impacts to patient monitoring at large

หัวข้อแนะนำ

SequencingRED 2020Rare Diseases
สิ่งที่ต้องอ่านถัดไป
  • C-Suite Perspectives, Event Coverage, Healthcare Transformation, Management, RED 2024
Dr William Morice II’s visions and considerations for building a global diagnostics ecosystem
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top